Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. VP Chief Financial Officer | November 09, 2020 | November 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date November 09, 2020 · Filed November 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,463 |
Ending reported balance
After 2020-11-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-11-09 · Exercise / conversion · Acquired 5,000 · Balance 49,463 F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Row 2 · 2020-11-09 · Sale · Disposed 5,000 · Balance 44,463 F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.98 · Expires 2026-03-01 | Direct | 10,000 |
Reported balance
After 2020-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-09 · Exercise / conversion · Disposed 5,000 · Balance 10,000 F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. F2: The option vests in four equal annual installments beginning on March 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020.
F2: The option vests in four equal annual installments beginning on March 1, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2017 Filed Apr 26, 2017 16:17 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 50,000 | $5.88 | $294,000.00 |
DisclosureSEC source: 0001104659-17-026371 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:58 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012175 · a4.xml · derivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-24 F2 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document |
| September 16, 2016 Filed Sep 16, 2016 17:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 2,000 | $25.00 | $50,000.00 |
DisclosureSEC source: 0001104659-16-145199 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015, as amended May 9, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.